CN Patent

CN119546312A — 用于治疗银屑病的包含a3腺苷受体激动剂的药物组合物

Assigned to Can Fite Biopharma Ltd · Expires 2025-02-28 · 1y expired

What this patent protects

本发明涉及用于治疗银屑病的方法和药物组合物，该药物组合物包含作为活性成分的匹立迪松(IB‑MECA)，所述活性成分的量适合以约6毫克(mg)的日剂量施用。

USPTO Abstract

本发明涉及用于治疗银屑病的方法和药物组合物，该药物组合物包含作为活性成分的匹立迪松(IB‑MECA)，所述活性成分的量适合以约6毫克(mg)的日剂量施用。

Drugs covered by this patent

Patent Metadata

Patent number
CN119546312A
Jurisdiction
CN
Classification
—
Expires
2025-02-28
Drug substance claim
No
Drug product claim
No
Assignee
Can Fite Biopharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.